Together, these results suggest that IPS-1 induces anticancer activity in an IFNβ-independent manner by regulating TRAIL, BCL2, BIRC3 and PRKCE. Previous reports have suggested that NDV replicates selectively in various cancer cells due to an impaired ability to produce type I IFN. Here, BIRC3 is linked to cancer.